FormularyWatch

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health. https://lnkd.in/eNqjRV3f

Almost half of those surveyed by Navitus Health Solutions said they’ve been unable to fill a needed prescription because of cost. https://lnkd.in/gNqtAGnF

An FDA advisory committee last year agreed that the data do not support phenylephrine as an effective nasal decongestant. https://lnkd.in/eX7eCRrT

Join Managed Healthcare Executive Managing Editor Peter Wehrwein discuss how the recent election will impact U.S. healthcare. He will moderate a discussion with Ryann Hill, Patrick Cooney and Lindsay Bealor Greenleaf, on Thursday, Nov. 14. Hear what healthcare experts have to say on what this could mean for the Affordable Care Act, Inflation Reduction Act, Medicare Advantage, and public health policies. #election2024 Register today: https://bit.ly/3NUinVB

Clinicians have very strong concerns about the cost of biologics to treat food allergies, but despite these concerns, enthusiasm in the field for their use remains very high. https://lnkd.in/eEXgvjfS

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). https://lnkd.in/eJahvCc4

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024. https://lnkd.in/ehVY-bCV

ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700. https://lnkd.in/eGTkrBKZ

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs. https://lnkd.in/ewVV_y5d

Sanjula Jain of Trilliant Health talks about how employers are best positioned to demand value for money from the U.S. healthcare system. https://lnkd.in/e4ThaJ-W